A Rollover Safety Study of Lumacaftor/Ivacaftor in Subjects Aged 2 Years and Older With Cystic Fibrosis, Homozygous for the F508del-CFTR Mutation

NCT03125395 · clinicaltrials.gov ↗
PHASE3
Phase
COMPLETED
Status
57
Enrollment
INDUSTRY
Sponsor class

Conditions

Interventions

Sponsor

Vertex Pharmaceuticals Incorporated